Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
SHATTUCK LABS Aktie jetzt für 0€ handeln | |||||
Do | Shattuck Labs, Inc.: Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel | 2 | GlobeNewswire (USA) | ||
26.08. | Shattuck Labs closes $103 million private placement led by OrbiMed | 2 | Investing.com | ||
26.08. | Shattuck Labs, Inc.: Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors | 1 | GlobeNewswire (USA) | ||
26.08. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
22.08. | H.C. Wainwright maintains Neutral rating on Shattuck Labs stock as FDA clears IND | 2 | Investing.com | ||
21.08. | Shattuck Labs, Inc.: Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease | 303 | GlobeNewswire (Europe) | - SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other inflammatory and immune-mediated diseases - - The Company... ► Artikel lesen | |
14.08. | Leerink Partners senkt Kursziel für Shattuck Labs auf 2 $ | 1 | Investing.com Deutsch | ||
14.08. | Shattuck Labs stock price target lowered to $2 by Leerink Partners | 1 | Investing.com | ||
14.08. | Shattuck Labs GAAP EPS of -$0.24 in-line | 2 | Seeking Alpha | ||
14.08. | Shattuck Labs, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
14.08. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
14.08. | Shattuck Labs, Inc.: Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights | 104 | GlobeNewswire (Europe) | - Submitted Investigational New Drug (IND) application to evaluate SL-325 in a Phase 1 clinical trial in healthy volunteers; clearance expected in Q3 2025 - - On track to dose first participant in... ► Artikel lesen | |
05.08. | Shattuck Labs stock soars after $103 million private placement | 4 | Investing.com | ||
05.08. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
05.08. | Shattuck Labs, Inc.: Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million | 5 | GlobeNewswire (USA) | ||
15.07. | Shattuck Labs: Aktionäre wählen Direktoren und bestätigen Wirtschaftsprüfer auf jährlicher Hauptversammlung | 1 | Investing.com Deutsch | ||
15.07. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
01.05. | Shattuck Labs GAAP EPS of -$0.27 beats by $0.01 | 1 | Seeking Alpha | ||
01.05. | Shattuck Labs, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
01.05. | Shattuck Labs, Inc.: Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights | 159 | GlobeNewswire (Europe) | - Company advances SL-325 program with an IND filing expected in the third quarter of 2025 - - Cash balance of approximately $60.9 million as of March 31, 2025, expected to fund operations into 2027... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
NUREXONE BIOLOGIC | 0,614 | +1,99 % | NurExone stärkt IP-Portfolio und Positionierung im Zukunftsmarkt der Exosomen-Therapien | ||
ONCO-INNOVATIONS | 1,000 | -0,99 % | Onco-Innovations schreitet mit präklinischem Programm fort: Nucro-Technics beginnt mit der Entwicklung von Analysemethoden für die PNKP-Technologie | Vancouver, Kanada - 28. September 2025 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (FWB: W1H, WKN: A3EKSZ) ("Onco" oder das "Unternehmen") freut sich bekannt zu geben... ► Artikel lesen | |
PRECIGEN | 2,824 | -1,12 % | Precigen stock rating reiterated as Overweight by Cantor Fitzgerald | ||
ALECTOR | 2,580 | -4,44 % | Alector, Inc.: Alector Provides Executive Leadership Update | -- Neil Berkley, M.B.A., appointed Interim Chief Financial Officer, succeeding Marc Grasso, M.D., effective June 20, 2025 -- SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Alector... ► Artikel lesen | |
KORRO BIO | 45,770 | +4,25 % | Korro Bio, Inc.: Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110 | CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based... ► Artikel lesen | |
ALX ONCOLOGY | 1,895 | 0,00 % | ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer | Dr. Barbara Klencke is an accomplished clinical leader with a distinguished track record in oncology drug development who currently serves on the Company's Board of Directors and will step down from... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,520 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
TAYSHA GENE THERAPIES | 4,880 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome | Breakthrough Therapy designation granted based on FDA's review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trials Finalized... ► Artikel lesen | |
QIAGEN | 39,470 | +0,71 % | Kaum Impulse für die Qiagen NV-Aktie (37,58 €) | Wenig Kursbewegung zur Stunde bei dem Anteilsschein von Qiagen NV . Der jüngste Kurs betrug 37,58 Euro. Einen minimalen Wertanstieg von 0,17 Prozent zeigt die Kurstafel für der Anteilsschein von Qiagen... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 44,180 | +2,74 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
EVOTEC | 6,612 | +4,36 % | Evotec Aktie - das große Zittern: Kurssturz Richtung 5 Euro? | Wieder ein Fehlausbruch bei der Evotec Aktie: Der Biotech-Titel hat diesmal bereits an der 50-Tage-Linie den Weg nach unten angetreten - zuvor passierten diese Fehlausbrüche an der spürbar höher liegenden... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 7,460 | 0,00 % | Aktien Europa: Leichte Gewinne zum Wochenauftakt | AMSTERDAM/LONDON/PARIS/ZÜRICH (dpa-AFX) - Europas wichtigste Aktienmärkte starten am Montag zunächst freundlich in die neue Woche. Allerdings blieb die Risikobereitschaft verhalten angesichts der bleiben... ► Artikel lesen | |
VERA THERAPEUTICS | 29,190 | +1,39 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 4, 2025, the Compensation Committee of Vera's Board of Directors granted... ► Artikel lesen | |
STRUCTURE THERAPEUTICS | 26,620 | +2,23 % | Aktien New York: Weitere Rekorde - auch dank Nvidia und Apple | NEW YORK (dpa-AFX) - Die US-Börsen haben am Montag nach einem verhaltenen Start ihre Rekordjagd fortgesetzt. Auch dank deutlicher Kursgewinne der Schwergewichte Nvidia und Apple verzeichnete der Leitindex... ► Artikel lesen | |
KINIKSA PHARMACEUTICALS | 37,470 | 0,00 % | What Analysts Are Saying About Kiniksa Pharmaceuticals Stock |